botulinum toxins

Revance DAXI Takes Next Step Toward FDA Approval

Revance Files BLA for DAXI

Revance Therapeutics has submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for DaxibotulinumtoxinA for Injection (DAXI) in the treatment of moderate to severe glabellar (frown) lines. The submission includes results from the three SAKURA Phase 3 trials in which DAXI demonstrated that half of the patients treated maintained none or only mild frown lines for at least 24 weeks (approximately six months) after a single treatment.

BTX Ability To Contract Dermal Fibroblasts Varies by Formulation and Dilution

How Botulinum Toxins Lift Skin

Intradermal botulinum toxin injections can cause dermal fibroblast contraction, providing a lifting effect for facial rejuvenation, but this effect varies based on brand and dilution. In an effort to determine how—and whether—intradermal botulinum toxins create visible lifting in the midface, researchers Rungsima Wanitphakdeedecha MD, MA, MSc, et al, treated normal human dermal fibroblasts with onabotulinumtoxin (ONA), abobotulinumtoxin (ABO), prabotulinumtoxinA (PRABO), incobotulinumtoxinA (INCO), and letibotulinumtoxin A (LETI) in varying dilutions.

Revance Appoints New President of Aesthetics and Therapeutics

Revances appoints new CCO of Aesthetics

Revance Therapeutics, a biotechnology company developing botulinum toxin products for aesthetic and therapeutic concerns has appointed Todd Zavodnick to chief commercial officer and president of its Aesthetics & Therapeutics division. Zavodnick will report to Revance’s CEO Dan Browne, and lead the company’s commercial operations along with the launch of its injectable daxibotulinumtoxinA (RT002).

Anterios Announces Development Of Next-Generation Injectable Neurotoxin

Anterios Announces Development Of Next-Generation Injectable Neurotoxin

Anterios, a privately held aesthetic medicine and medical dermatology biopharmaceutical company, has announced development of a next-generation injectable botulinum toxin product, AI-09. Unlike currently commercialized botulinum toxin products that require reconstitution prior to injection, AI-09 will be packaged as a ready-to-use injectable liquid and is a complementary product to the company's topical botulinum prescription Phase IIb product ANT-1207, which is being developed for wrinkles, hyperhidrosis (excessive sweating) and acne.

Recognizing Complications

Protect your practice and patients by training staff to recognize potentially serious adverse events.
Main Image: 
Recognizing complications

Noninvasive cosmetic procedures have surged in popularity thanks to their affordability, effectiveness and strong safety profiles. Still, serious complications—including necrosis, infection and allergic reaction—can occur. In medical aesthetic practices, front desk staff and office managers are often the first to field calls from concerned patients. Training these staff members to differentiate between normal reactions that are part of the healing process and undesirable or dangerous complications is crucial to postprocedure care.